Core Viewpoint - The recent transfer of shares by BioNTech (06955) indicates a strategic move involving significant shareholder activity and potential market implications [1] Group 1: Shareholder Activity - On January 26, BioNTech's shareholders transferred shares from China Securities Depository and Clearing Hong Kong to CITIC Securities Brokerage Hong Kong, with a market value of HKD 346 million, representing 6.32% of the total shares [1] Group 2: Corporate Actions - BioNTech's board has been informed by its controlling shareholder, Green Leaf Pharmaceutical Group, about plans to transfer 11.9866 million H-shares to the market through its wholly-owned subsidiary, Shandong Green Leaf Pharmaceutical Co., Ltd., scheduled for January 27, 2026 [1]